

Structural and metabolic retinal changes associated with mild cognitive impairment in type 2 diabetes

Pedersen, Frederik N; Stokholm, Lonny; Lois, Noemi; Yang, Dawei; Cheung, Carol Y; Biessels, Geert Jan; Exalto, Lieza; Simó, Rafael; Peto, Tunde; Pouwer, Frans; Grauslund, Jakob

Published in:
Diabetes

DOI:
10.2337/db23-0025

Publication date:
2023

Document version:
Accepted manuscript

Citation for published version (APA):

Pedersen, F. N., Stokholm, L., Lois, N., Yang, D., Cheung, C. Y., Biessels, G. J., Exalto, L., Simó, R., Peto, T., Pouwer, F., & Grauslund, J. (2023). Structural and metabolic retinal changes associated with mild cognitive impairment in type 2 diabetes. *Diabetes*, 72(12), 1853-1863. <https://doi.org/10.2337/db23-0025>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Title:

Structural and metabolic retinal changes associated with mild cognitive impairment in type 2 diabetes

Running Title:

Retinal markers of cognitive impairment

Authors:

Frederik N Pedersen, MD^{1,2}

Lonny Stokholm, PhD^{2,3}

Noemi Lois, PhD⁴

Dawei Yang, PhD⁵

Carol Y Cheung, PhD⁵

Geert Jan Biessels, PhD⁶

Lieza Exalto, PhD⁶

Rafael Simó, PhD⁷

Tunde Peto, PhD^{2,4}

Frans Pouwer, PhD^{8,9}

Jakob Grauslund, DMSci^{1, 2, 9}

Affiliations:

1. Department of Ophthalmology, Odense University Hospital, Odense, Denmark
2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark
3. OPEN – Open Patient data Explorative Network, Odense University Hospital & University of Southern Denmark, Odense, Denmark
4. Wellcome-Wolfson Institute for Experimental Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, Northern Ireland, United Kingdom

5. Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
6. Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands
7. Department of Endocrinology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR) and CIBERDEM (ISCIII), Barcelona, Spain
8. Department of Psychology, University of Southern Denmark, Odense, Denmark.
9. Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark

Corresponding author:

Frederik Nørregaard Pedersen, MD

Department of Ophthalmology

Odense University Hospital

J. B. Winsløvs Vej 4

5000 Odense C

Denmark

Phone: +45 3134 1503

E-mail: Frederik.norregaard.pedersen@rsyd.dk

Word count: 3112

Tables and Figures: 5 tables and 2 figure.

1

2 **Abstract**

3 Type 2 diabetes is associated with cognitive impairment and a twofold increased risk of dementia
4 compared to age-matched individuals without diabetes. Given that the eye and the brain share similar
5 embryologic origin and anatomical features the retina offers a unique “window” to the brain. In this
6 study we wanted to determine whether there was a difference in retinal imaging-based neuronal and
7 vascular markers in individuals with type 2 diabetes with or without minimal cognitive impairment
8 (MCI). We included 134 persons with type 2 diabetes. Based on neuropsychological tests the
9 prevalence of MCI was 28%. We performed 7-field color fundus photos, optical coherence tomography
10 (OCT), OCT-Angiography and retinal oximetry in order to analysis retinal markers. In a multivariable
11 cluster analysis, persons with MCI had significant thinner macular retinal nerve fiber layer and macular
12 ganglion cell layer, and less venular oxygen saturation in the nasal quadrant compared to those without
13 MCI. There were no differences in retinal vessel density, fractal dimension, width, tortuosity or OCT-A
14 markers. People with type 2 diabetes and MCI demonstrate alterations in retinal structure and
15 metabolism, suggesting non-invasive retinal markers may be useful to detect those at risk of cognitive
16 dysfunction in people with type 2 diabetes.

17

18

19 **Highlights:**

- 20 • **Why did we undertake this study?**
- 21 • **Type 2 diabetes is associated with minimal cognitive impairment (MCI). Therefore**
22 **retinal and cerebral neurodegeneration may run in parallel.**
- 23 • **What is the specific question(s) we wanted to answer?**
- 24 • **To assess whether there was a difference in retinal structure, vessel and metabolic**
25 **parameters in individuals with MCI.**
- 26 • **What did we find?**
- 27 • **We found those with MCI had thinner macular retinal nerve fiber layer, macular**
28 **ganglion cell layer and less venular oxygen saturation.**
- 29 • **What are the implications of our findings?**

30 • **We suggest non-invasive retinal markers may be useful to detect those at risk of**
31 **cognitive dysfunction.**

32

33 **Introduction**

34 Type 2 diabetes (T2DM) is associated with mild cognitive impairment (MCI), which is characterized
35 by objective cognitive deficits on standard neuropsychological tests without affecting daily living [1].
36 The World Health Organization predicts a rapid increase in the number of individuals with T2DM and
37 incident cognitive impairment, with an annual conversion rate from MCI to dementia of around 10%
38 [2] and almost twofold higher risk of developing dementia in individuals with T2DM compared to age-
39 matched individuals without diabetes [3]. Since diagnostics of MCI rely on extensive
40 neuropsychological testing, there is a need to identify those at increased risk of cognitive impairment to
41 ensure early diagnosis in order to manage modifiable risk factors (e.g. metabolic control) to slow
42 progression of cognitive loss and to provide them with appropriate support.

43 Diabetes itself causes structural and vascular changes to the retina even in the absence of diabetic
44 retinopathy (DR) [4]. This is considered related to retinal neurodegeneration and microangiopathy
45 resulting in damage to the neurovascular unit ultimately leading to instability of the retina-blood-barrier
46 [5]. As the retina and the brain share similar embryologic origin, retinal imaging might be useful to
47 detect early pathology in the cerebral vasculature and parenchyma, as retinal and cerebral
48 neurovascular degeneration often run in parallel [6]. This may provide researchers and clinicians the
49 opportunity to utilize non-invasive retinal imaging-based markers for identifying individual with high
50 risk for cognitive impairment and dementia.

51 Retinal sensitivity and eye fixation assessed by microperimetry have been proposed as non-invasive
52 retinal tools for identifying and monitoring MCI in people with T2DM [7, 8]. Other retinal structural
53 and metabolic markers have been less investigated within the T2DM population. A single cross-
54 sectional study of 137 participants with T2DM reported venular tortuosity to be higher in persons with

55 cognitive impairment compared to healthy controls, but the study used a telephone interview only to
56 assess cognitive status [9].

57 Therefore, the aim of the present study was to determine whether there was a difference in retinal
58 imaging-based neuronal and vascular markers in individuals with T2DM with or without MCI.

59

60 **Research Design and Methods**

61 **Study population**

62 This was a prospective cross-sectional study including individuals with T2DM identified using the
63 Funen Diabetes Database (FDDB), a regional diabetes database in the area of Southern Denmark
64 established in 2003 [10]. The database provides information on relevant clinical information, including
65 for example age, type of diabetes, body mass index (BMI), blood pressure, DR screening results and
66 information on comorbidities, such as acute coronary syndrome and cerebrovascular incidents.

67 Potential eligible participants were invited to take part in this study using a secure digital mailbox [11],
68 distributed for each citizens in Denmark between 25 November 2020 and 25 February 2022, and all
69 examinations were performed at Odense University Hospital. A pre-screening based on eligibility
70 criteria (inclusion and exclusion criteria) by telephone was performed in order to streamline
71 recruitment. Criteria for eligibility were diagnosis of T2DM, age above 65 years, duration of diabetes
72 of at least 5 years, and ability to provide informed consent. Individuals were excluded if they had a
73 diagnosis of stroke or any neurodegenerative disease, if retinal neurodegeneration was already known
74 to be present due to previous laser photocoagulation, glaucoma or diabetic macular edema or other eye
75 disorders affection vision besides possible complications of DR, refractive error ≥ 6 diopters, media
76 opacities precluding retinal imaging, severe systemic illness or personal circumstances that would

77 prevent the subject to fulfil the study protocol. If deemed eligible, individuals were allowed to
78 participate with both eyes under the assumption that retinal changes may not be seen symmetrically.

79

80 **Clinical examination**

81 A medical and ophthalmological history as well as demographics (year of birth, sex, education) were
82 obtained. Current use of antidiabetic agents and blood pressure medication was recorded. Duration of
83 diabetes was obtained from the FDDDB and cross checked with medical records. If a discrepancy was
84 seen between medical records and FDDDB, the earliest year of diagnosis was used to calculate diabetes
85 duration. Marital status was categorized as having a partner or single. We measured weight and height
86 and calculated BMI as well as abdominal circumference. Smoking status was registered as never,
87 former or current smoker. Brachial arterial blood pressure was measured with participants sitting with
88 Omron M6 (HEM-7001-E, Hoofddorp, The Netherlands), and mean arterial pressure was calculated as
89 $BP_d + (BP_d + BP_s) / 3$ where BP_d and BP_s are the diastolic and systolic blood pressure, respectively. In
90 addition, fasting (minimum 4 hours) venous blood samples were drawn to collect information on blood
91 glucose levels, lipid profile, and renal function. Participants collected a morning urine sample to
92 measure albuminuria; this was defined as normo-albuminuria if $< 30\text{mg/g}$; micro-albuminuria if
93 between $30\text{-}300\text{ mg/g}$, and macro-albuminuria when $>300\text{ mg/g}$. The geriatric depression score-15 was
94 used to detect presence of depressive symptoms.

95

96 **Cognitive assessment**

97 All participants underwent a stepwise neuropsychological evaluation. Firstly, the Montreal Cognitive
98 Assessment (MoCA) test was administered by a certified physician. Those with a MoCA score below
99 26 were considered to have potential cognitive impairment and were subsequently tested with a

100 neuropsychological test battery (NTB). The NTB comprised 13 tests covering five cognitive domains;
101 processing speed (Digit Symbol Substitution Test and Trail-Making-Test A); attention and executive
102 functioning (Trail-Making-Test B, letter fluency and backwards digit span); memory (Rey Auditory
103 Verbal Learning Test direct, delayed and recognition, Rey-Österrieth Complex Figure Test delayed and
104 forward digit span); visio-construction (Rey-Österrieth Complex Figure Test copy) and language
105 (Boston Naming Test and Category fluency). Test scores were converted to percentile scores according
106 to reference data [12-17]. Individuals were considered to have MCI if the average score of one or more
107 domains were below the 15th percentile or if over half of the tests in a single domain were below the 5th
108 percentile [18].

109

110 Outcome

111 We performed multiple imaging technologies. Our primary outcome is difference in retinal vessel
112 saturation whereas secondary outcomes include differences in retinal vascular and structural
113 parameters. Each retinal parameter will be described in the following sections.

114

115 **Ophthalmologic examination**

116 Best-corrected visual acuity (BCVA) was obtained prior to pupil dilation and prior to the undertaking
117 of any imaging evaluations (see below), using Early Treatment Diabetic Retinopathy Study charts at 4
118 meters (Precision Vision, Illinois, USA). We performed a dilated eye examination using tropicamide
119 10 mg/ml and phenylephrine 10% including 45 degree 7-field color fundus photography (TRC-50DX
120 fundus camera, Topcon, Tokyo, Japan). DR grading was undertaken by a certified grader according to
121 the International Clinical Diabetic Retinopathy Disease Severity Scale [19], with each eye categorized

122 as level 0 (no DR), 1 through 3 (mild, moderate and severe none-proliferative DR), or 4 (proliferative
123 DR).

124

125 **Structural retinal microvascular markers**

126 *OCT markers*

127 Central retinal thickness was measured using SD-OCT (Spectralis OCT Family Acquisition Module,
128 V6.9a Heidelberg Engineering, Germany). OCT imaging acquisition settings were high speed, volume
129 scan with ART 9. The automated segmentation protocol of the Spectralis OCT (Heidelberg Eye
130 Explorer V1.10.2.0) was used to measure macular ganglion cell layer (mGCL) thickness and macular
131 retinal nerve fiber layer (mRNFL) thickness. The automated segmentation was manually corrected for
132 any misalignments. The scans were divided according to the ETDRS map into 1 mm, 3 mm and 6 mm
133 rings. The inner ring was defined as the central thickness subfield, and the outer rings were divided into
134 four zones designated as the superior, nasal inferior and temporal zones.

135

136 *Retinal vessel analysis*

137 Retinal structures including vessel width, density, tortuosity and fractal dimension were assessed using
138 VAMPIRE-Web (Vessel Assessment and Measurement Platform for Images of the Retina, Universities
139 of Dundee and Edinburgh, UK) [20]. In brief, 45-degree disc centered, color fundus photos were used,
140 and three concentric zones were semi-automatically generated around the optic disc labeled zone A, B
141 and C at 0.0-0.5, 0.5-1.0 and 0.5-2.0 disc diameters from the disc margin, respectively. The software
142 color labelled venules blue and arterioles red. In cases where the software mislabeled retinal vessels,
143 detected one vessel as two, or labelled a hemorrhage the annotation was manually corrected. The

144 retinal vessel width was calculated as the central retinal artery (CRAE) and vein equivalent (CRVE) in
145 zone B [21]. Vessel density, tortuosity and fractal dimension were measured in zone C [22].

146

147 *OCT-A markers*

148 Macula centered 4.5x.4.5 mm OCT-A images were obtained with TRC-50DX fundus camera (Topcon,
149 Tokyo, Japan). MATLAB (MathWorks, Natick, MA) was used for quantification of retinal
150 microvasculature from OCT-A images, as previous described [23]. In short, markers of interest were (I)
151 the area of the foveal avascular zone (FAZ) given by the total numbers of pixels within the region, (II)
152 non-perfusion regions defined as dark areas from a binarized image larger than 0.02mm, (III) vessel
153 density within the ETDRS grid (1, 3 mm) calculated as the areas not defined as non-perfusion regions
154 over total area of the interested region, and (IV) fractal dimension calculated using a box-counting
155 method in a skeletonized image. All the markers were measured in the superficial capillary plexus
156 (SCP) and deep capillary plexus (DCP). We excluded scans with image quality below 40 according to
157 Topcon software.

158

159 **Measures of retinal oxygen saturation**

160 Retinal vessel oxygen saturation measurements were performed in 50-degree disc centered images
161 using the Oxymap Model T1 [24]. In short, two concentric circles were semi automatically placed
162 around the optic disc with diameters 1.5 times and 3 times the optic disc diameter. The largest venule
163 and arteriole in each quadrant were annotated in length between 50-200 um [25]. We performed both
164 mean and quadrant arterial and venular saturation analyses. Images with quality below five were
165 excluded according to the Oxymap software.

166

167 **Ethical and Institutional Review Board (IRB) approvals**

168 The study was performed according to the tenets of the Helsinki Declaration, and relevant permissions
169 were obtained from the Region of Southern Denmark's record of data processing activities (Journal
170 number 20/34731) and from the Danish National Committee on Health Research Ethics (S-20200050).
171 The study was registered at <http://www.clinicaltrials.gov> before initiation (NCT04610749). Written
172 informed consent was obtained from all participants.

173

174 **Statistical analysis**

175 Study sample characteristics are presented in Table 1 with categorical data presented with numbers and
176 percentages, and numerical data with medians and interquartile range (IQR). Given that data from both
177 eyes of participants were included, mixed model regression analysis with cluster robust standard error
178 was used to test for difference in retinal markers between persons with and without MCI. We
179 performed an unadjusted crude model and a multivariable model adjusting for age, sex, mean arterial
180 pressure and presence (yes/no) of DR. Due to interaction between DR and MCI, we reported results
181 for the entire group as well as stratified in groups with and without overt DR (Table 5). In a secondary
182 analysis we calculated area under the curve for retinal parameters that were associated with MCI
183 adjusted for age, sex, mean arterial pressure and presence of DR (Supplementary material). Missing
184 data was considered as missing at random which included abdominal circumference (n=1), total
185 cholesterol (n=1), LDL cholesterol (n=2), estimated glomerular filtration rate (n=1), albumin
186 excretion rate (n=1). In data available for regression analysis there were no missing values.. P-values
187 below 0.05 were considered statistically significant. The study included multiple analysis, thus risk for
188 spurious findings. We performed Bonferroni corrections based on 83 initial analysis. Results that were

189 still statistical significant after corrections are annotated in the tables. Abovementioned statistics were
190 performed with STATA version 17.0 (StataCorp LLC, College Station, TX, USA).

191 Sample size was based on previous results regarding retinal vessel saturation and prevalence of MCI in
192 T2DM. Power was performed by conducting a statistical power analysis using PROC POWER in SAS.
193 With 200 included persons using a significance level of 5% the power would be 86%. With a reduction
194 to 120 included participants the power would reduce to 80 % on a significance level of 5%.

195

196 **Data and Resource Availability**

197 Data is available upon reasonable request to the author.

198

199 **Results**

200 Overall, 134 participants (245 eyes) were eligible and included in this study (Figure 1). Upon
201 reviewing MoCA scores, 65 participants scored below 26 points, of whom 38 participants (28% of the
202 overall group) were categorized with MCI based on NTB results. The number of total impaired
203 cognitive domains varied with 17, 11, 8 and 2 participants impaired in 1, 2, 3 and 4 domains,
204 respectively. The most frequent domain impaired was memory (impaired in n= 18; 47%), and the least
205 language (impaired in n= 8; 21%) (Figure 2).

206 Compared to individuals without MCI, participants with MCI had completed fewer years of education
207 (9.0 years vs. 11.0 years $p < 0.001$) and were more often taking glucose lowering treatment, excluding
208 insulin (97% vs 83% $p = 0.028$) (Table 1). Persons with MCI had statistically significantly worse BCVA
209 (84.0 vs 84.5 $p = 0.035$) compared to individuals without MCI, but there was no difference between
210 history of cataract surgery or presence of any overt DR. There were no difference between presence of

211 DR (yes/no) and MCI (32% vs. 21% $p=0.23$). In addition, sex, age, diabetes duration, marital status,
212 BMI, smoking, blood pressure or history of ischemic heart disease was comparable between the two
213 groups. There were no differences detected in HbA_{1c}, cholesterol levels, estimated glomerular
214 filtration rate, or albumin excretion rate between those with or without MCI.

215 In a mixed regression model adjusted for age, sex, mean arterial pressure and presence of DR, mRNFL
216 was thinner in the superior sector (inner region) ($22.3\mu\text{m}$ vs. $24.1\mu\text{m}$ $p=0.007$), nasal sector (inner)
217 ($20.5\mu\text{m}$ vs. $21.7\mu\text{m}$ $p=0.049$) and nasal sector (outer region) ($43.3\mu\text{m}$ vs. $46.5\mu\text{m}$ $p=0.032$) in
218 individuals with MCI compared with those without MCI. This was also seen in the mGCL, with
219 thinning in the inner region ($p=0.029$), inner superior ($p=0.029$), nasal ($p=0.010$), and inferior (0.027)
220 sector in individuals with MCI compared to those without MCI. Likewise, participants with MCI had
221 central macular thinning in the inner superior ($p=0.018$) and nasal ($p=0.033$) sectors when compared to
222 those without MCI, after adjustment of age, sex and presence of DR (Table 2).

223 There was no statistically significant difference in vessel width for either arterioles or venules, vessel
224 tortuosity, density or fractal dimension in the crude or adjusted model between groups (with or without
225 MCI) (Table 3). Likewise, there was no statistical significant association between OCT-A markers
226 including FAZ, macular vessel density or fractal dimension in the SCP or DCP and presence or
227 absence of MCI (Table 4).

228 Compared to those without MCI, participants with MCI had lower venular saturation of oxygen in the
229 upper nasal quadrant (61.0% vs. 56.4% $p=0.028$) in the adjusted model, but this was no longer
230 statistically significant after stratification for presence of DR in the model (Table 5). There were also
231 no statistically significant differences in mean retinal arterial or venular oxygen saturation levels
232 between both groups. In an adjusted model for age, sex, mean arterial pressure and presence of DR the

233 AUC varied between 0.65-0.68 for retinal parameters where we found a statistical significant
234 association (Supplementary material).

235

236 **Discussion**

237 In the present study, 28% of T2DM participants fulfilling our criteria of MCI, had retinal neurovascular
238 alterations based on the presence of a decreased thickness in the mRNFL as well as lower venular
239 oxygen saturation in the upper nasal quadrant. We did not find any statistically significant differences
240 in retinal vessel caliber, tortuosity, density, fractal dimension or OCT-A markers.

241 The prevalence of MCI in people with T2DM in the current study is lower than that found in a recent
242 meta-analysis, which reported prevalence of 45% with rates ranging from 22% to 68% [26]. This
243 systematic review included ten studies from Asia and two from Europe and reported a lower overall
244 prevalence of MCI in European studies (37% vs 46%). However, this was not directly comparable to
245 our study, as the European studies used Mini-Mental State Examination (MMSE) and MoCA to assess
246 MCI, whereas MoCA was used as screening for possible cognitive dysfunction in the present study,
247 supplemented by a robust NTB [27, 28]. In general, MMSE and MoCA are used as screening tests for
248 cognitive impairment, which may have resulted in false positive MCI cases in the before mentioned
249 studies, and caused the observed higher prevalence compared to our study.

250 Regarding retinal markers for MCI in T2DM, the thinning of mRNFL and mGCL found in the present
251 study for those with T2DM and MCI is comparable with previous findings in samples without diabetes
252 [29]. The thinning of the retinal layers may reflect a potential concurrent retinal and cerebral
253 neurodegeneration. A recent large Magnetic Resonance Imaging study including 2131 participants
254 reported no association between mRNFL thinning and a smaller brain volume. However, mRNFL
255 thinning was found to be correlated with volume reduction in the occipital-parietal cortex in people

256 with multiple sclerosis [30, 31]. In this study, most of the differences in retinal parameters were found
257 in the inner region. This could indicate that MCI is associated with lesions in specific retinal areas.
258 This is strengthened by magnetic resonance imaging studies that have shown an association between
259 regional changes in the mRNFL and regional cerebral atrophy in individuals with high genetic risk of
260 AD [32], however it should be noted that results are inconsistent while others have not found a positive
261 association [33]. Therefore, it remains uncertain whether retinal thinning could be a proxy
262 measurement for cerebral degeneration.

263 We did not find any differences in retinal fractal dimension. Previous findings regarding fractal
264 dimension and MCI have been inconsistent. For example a population-based-cross sectional study of
265 1202 participants found that cognitive impairment was more common in those with lower fractal
266 dimensions, but in a subgroup analysis stratified for diabetes this association was no longer significant
267 [34]. Furthermore, a recent cross-sectional study of 1431 participants, of which 22% had diabetes,
268 found no significant association between fractal dimension and MCI [35]. Differences in results may be
269 due to different variables considered relevant for the regression model used. Thus, while Cheung et al.
270 [34] adjusted for age, sex, low income, low education, hypertension, smoking, hyperlipidemia and
271 chronic kidney disease, O'Neill et al. [35] corrected for age, sex, alcohol consumption, smoking status,
272 educational attainment, physical activity, history of cardiovascular disease, hypertension triglycerides,
273 diabetes, medication, mean arterial blood pressure, body mass index and high-density lipoprotein.
274 A previous cross-sectional study of 137 individuals with newly diagnosed T2DM found a higher
275 venular tortuosity in persons diagnosed with cognitive dysfunction by a telephone interview, but no
276 alterations were observed in vessel width, fractal or arterial tortuosity [9]. Our study does not support
277 an altered venular tortuosity in individuals with T2DM and MCI, but differences in results may be due
278 to a dissimilarity in the analysis software used to assess vessel tortuosity. Differences in results may

279 also relate to differences in the accuracy of the diagnosis of cognitive impairment between studies
280 (phone interview versus detailed NTB). In general retinal vessel width, fractal dimension and retinal
281 vessel tortuosity has been associated with other disorders, including cardiovascular disease [36] and
282 cerebrovascular disease [37], which may indicate that this marker, on its own, may be to unspecific.
283 In the present study, the retinal venular oxygen saturation in the nasal quadrant appeared to be lower in
284 participants with MCI when compared to those without, although this was not statistically significantly
285 different after statistical adjustments. A small study including 42 people with MCI and healthy controls
286 found increased mean venular and arterial saturation in those with MCI, however diabetes was an
287 exclusion criteria and the study did not perform either a quadrant analysis which makes comparison
288 between studies difficult [38].

289 Strengths of the study include its prospective nature and the in-depth neuropsychological evaluation
290 which would be expected to have provided an accurate assessment of MCI, but we did not include
291 subjective cognitive complaints. Limitations include the relatively small number of participants and the
292 study's cross-sectional design , which does not allow causal relationships to be examined. Furthermore,
293 grading's of retinal markers were not obtained by investigators masked to the cognitive status of
294 participants. Lastly, caution should be made when interpreting the data presented, with the potential of
295 spurious assooiations due to multiple testing. It should be noted that only few associations were
296 statistical significant, but these might help guide future research.

297 In conclusion, we found MCI in almost one in three persons with T2DM, as well as changes in retinal
298 structural and metabolic markers. Longitudinal studies are warranted to further investigate the temporal
299 associations of structural, metabolic and functional retinal markers in people with T2DM and MCI. On
300 this regard, the “retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways
301 and identification of patients at risk of dementia (RECOGNISED)” study (<https://www.recognised.eu/>),

302 funded by the European Union’s Horizon 2020, which includes cross-sectional and longitudinal
303 prospective clinical studies as well as experimental basic science studies, aims to elucidate biomarkers,
304 including retinal biomarkers, of risk of cognitive impairment as well as pathogenic mechanisms of
305 disease in people with T2DM.

306 **Acknowledgments:** Participants in the current study were also recruited for the “RECOGNISED”
307 study (NTC04281186), if deemed eligible. The Authors would like to acknowledge the RECOGNISED
308 (Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and
309 identification of patients at risk of dementia) consortium, funded by the European Union’s Horizon
310 2020 research and innovation programme under grant agreement No. 847749.

311 **Guarantors:** FNP is the guarantor of this work and, as such, had full access to all the data in the study
312 and takes responsibility for the integrity of the data and the accuracy of the data analysis.

313 **Author Contributions:** FNP recruited participants and performed the study. FNP analyzed the data
314 except OCT-A images which was done by DY and CYC. FNP and LS performed the statistical
315 analysis. FNP wrote the manuscript with input from all authors.

316 **Funding/Support:** This work was supported by Odense University Hospital PhD Foundation (grant
317 number 4339) and Overlægerådets forskningsfond (A4651).

318 **Conflict of Interest Disclosures:** None reported

319

320 References:

- 321 [1] Petersen RC (2016) Mild Cognitive Impairment. *Continuum (Minneap Minn)* 22(2 Dementia):
322 404-418. 10.1212/CON.0000000000000313
- 323 [2] Ma F, Wu T, Miao R, Xiao YY, Zhang W, Huang G (2015) Conversion of mild cognitive impairment
324 to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five
325 years of follow-up. *J Alzheimers Dis* 43(4): 1441-1449. 10.3233/JAD-141566
- 326 [3] Simo R, Ciudin A, Simo-Servat O, Hernandez C (2017) Cognitive impairment and dementia: a new
327 emerging complication of type 2 diabetes-The diabetologist's perspective. *Acta Diabetol* 54(5): 417-424.
328 10.1007/s00592-017-0970-5
- 329 [4] Chai Q, Yao Y, Guo C, Lu H, Ma J (2022) Structural and functional retinal changes in patients with
330 type 2 diabetes without diabetic retinopathy. *Ann Med* 54(1): 1816-1825. 10.1080/07853890.2022.2095010
- 331 [5] Little K, Llorián-Salvador M, Scullion S, et al. (2022) Common pathways in dementia and diabetic
332 retinopathy: understanding the mechanisms of diabetes-related cognitive decline. *Trends Endocrinol Metab*
333 33(1): 50-71. 10.1016/j.tem.2021.10.008
- 334 [6] Zhang Y, Wang Y, Shi C, Shen M, Lu F (2021) Advances in retina imaging as potential biomarkers
335 for early diagnosis of Alzheimer's disease. *Transl Neurodegener* 10(1): 6. 10.1186/s40035-021-00230-9
- 336 [7] Ortiz-Zúñiga Á M, Simó-Servat O, Rojano-Toimil A, et al. (2021) The Gaze Fixation Assessed by
337 Microperimetry: A Useful Tool for the Monitoring of the Cognitive Function in Patients with Type 2 Diabetes. *J*
338 *Pers Med* 11(8). 10.3390/jpm11080698
- 339 [8] Ciudin A, Simo-Servat O, Hernandez C, et al. (2017) Retinal Microperimetry: A New Tool for
340 Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease. *Diabetes* 66(12): 3098-
341 3104. 10.2337/db17-0382
- 342 [9] Naidu VV, Ismail K, Amiel S, et al. (2016) Associations between Retinal Markers of Microvascular
343 Disease and Cognitive Impairment in Newly Diagnosed Type 2 Diabetes Mellitus: A Case Control Study. *PLoS*
344 *One* 11(1): e0147160. 10.1371/journal.pone.0147160
- 345 [10] Adelborg K, Szentkúti P, Henriksen JE, et al. (2020) Cohort profile: the Funen Diabetes Database-
346 a population-based cohort of patients with diabetes in Denmark. *BMJ Open* 10(4): e035492. 10.1136/bmjopen-
347 2019-035492
- 348 [11] <https://www.nets.eu/developer/Nets%20share/ebokschannel/Pages/default.aspx>
- 349 [12] Vogel A, Stokholm J, Jørgensen K (2012) Performances on Rey Auditory Verbal Learning Test and
350 Rey Complex Figure Test in a healthy, elderly Danish sample--reference data and validity issues. *Scand J Psychol*
351 53(1): 26-31. 10.1111/j.1467-9450.2011.00909.x
- 352 [13] Vogel A, Stokholm J, Jørgensen K (2020) Normative data for eight verbal fluency measures in
353 older Danish adults. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn* 27(1): 114-124.
354 10.1080/13825585.2019.1593935
- 355 [14] Nielsen H, Lolk A, Kragh-Sørensen P (1995) Normative data for eight neuropsychological tests,
356 gathered from a random sample of Danes aged 64 to 83 years. *Nordisk Psykologi* 47(4): 241-255.
357 10.1080/00291463.1995.11863861
- 358 [15] Neuropsykologer KJoSD (2012) Danske normer til neuropsykologiske tests. Dansk Psykologisk
359 Forlag
- 360 [16] Mitrushina M, Boone K, Razani J, D'Elia L (2005) Handbook of Normative Data for
361 Neuropsychological Assessment
- 362 [17] Wechsler IV D (2010) WAIS-IV Administration and Scoring Manual (Wechsler Adult Intelligence
363 Scale—Fourth Edition). London: NCS Pearson

- 364 [18] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive
365 impairment: clinical characterization and outcome. *Arch Neurol* 56(3): 303-308. 10.1001/archneur.56.3.303
- 366 [19] Wilkinson CP, Ferris FL, 3rd, Klein RE, et al. (2003) Proposed international clinical diabetic
367 retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* 110(9): 1677-1682.
368 10.1016/S0161-6420(03)00475-5
- 369 [20] Perez-Rovira A, MacGillivray T, Trucco E, et al. (2011) VAMPIRE: Vessel assessment and
370 measurement platform for images of the REtina. *Annu Int Conf IEEE Eng Med Biol Soc* 2011: 3391-3394.
371 10.1109/IEMBS.2011.6090918
- 372 [21] Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BE (2003) Revised formulas for
373 summarizing retinal vessel diameters. *Curr Eye Res* 27(3): 143-149. 10.1076/ceyr.27.3.143.16049
- 374 [22] MacGillivray T, McGrory S, Pearson T, Cameron J (2018) Retinal Imaging in Early Alzheimer's
375 Disease. In: Pernecky R (ed) *Biomarkers for Preclinical Alzheimer's Disease*. Springer New York, New York, NY,
376 pp 199-212
- 377 [23] Tang FY, Ng DS, Lam A, et al. (2017) Determinants of Quantitative Optical Coherence
378 Tomography Angiography Metrics in Patients with Diabetes. *Sci Rep* 7(1): 2575. 10.1038/s41598-017-02767-0
- 379 [24] Geirsdottir A, Palsson O, Hardarson SH, Olafsdottir OB, Kristjansdottir JV, Stefánsson E (2012)
380 Retinal vessel oxygen saturation in healthy individuals. *Invest Ophthalmol Vis Sci* 53(9): 5433-5442.
381 10.1167/iovs.12-9912
- 382 [25]
383 https://oxymap.zendesk.com/hc/article_attachments/360005366331/Protocol%20for%20oxime
384 [try%2021%20Nov%202013.pdf](https://oxymap.zendesk.com/hc/article_attachments/360005366331/Protocol%20for%20oxime). Accessed 25/10/22 2022
- 385 [26] You Y, Liu Z, Chen Y, et al. (2021) The prevalence of mild cognitive impairment in type 2 diabetes
386 mellitus patients: a systematic review and meta-analysis. *Acta Diabetol* 58(6): 671-685. 10.1007/s00592-020-
387 01648-9
- 388 [27] Albai O, Frandes M, Timar R, Roman D, Timar B (2019) Risk factors for developing dementia in
389 type 2 diabetes mellitus patients with mild cognitive impairment. *Neuropsychiatr Dis Treat* 15: 167-175.
390 10.2147/ndt.S189905
- 391 [28] Gorska-Ciebiada M, Saryusz-Wolska M, Ciebiada M, Loba J (2014) Mild cognitive impairment and
392 depressive symptoms in elderly patients with diabetes: prevalence, risk factors, and comorbidity. *J Diabetes*
393 *Res* 2014: 179648. 10.1155/2014/179648
- 394 [29] Ge YJ, Xu W, Ou YN, et al. (2021) Retinal biomarkers in Alzheimer's disease and mild cognitive
395 impairment: A systematic review and meta-analysis. *Ageing Res Rev* 69: 101361. 10.1016/j.arr.2021.101361
- 396 [30] Khawaja AP, Chua S, Hysi PG, et al. (2020) Comparison of Associations with Different Macular
397 Inner Retinal Thickness Parameters in a Large Cohort: The UK Biobank. *Ophthalmology* 127(1): 62-71.
398 <https://doi.org/10.1016/j.ophtha.2019.08.015>
- 399 [31] Petroboni AM, Dell'Arti L, Caprioli M, et al. (2019) The loss of macular ganglion cells begins from
400 the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. *Mult Scler* 25(1): 31-
401 38. 10.1177/1352458517740214
- 402 [32] López-Cuenca I, Marcos-Dolado A, Yus-Fuertes M, et al. (2022) The relationship between retinal
403 layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer's disease: an
404 exploratory analysis. *Alzheimer's Research & Therapy* 14(1): 79. 10.1186/s13195-022-01008-5
- 405 [33] Jeevakumar V, Sefton R, Chan J, et al. (2022) Association between retinal markers and cognition
406 in older adults: a systematic review. *BMJ Open* 12(6): e054657. 10.1136/bmjopen-2021-054657
- 407 [34] Cheung CY, Ong S, Ikram MK, et al. (2014) Retinal vascular fractal dimension is associated with
408 cognitive dysfunction. *J Stroke Cerebrovasc Dis* 23(1): 43-50. 10.1016/j.jstrokecerebrovasdis.2012.09.002

- 409 [35] O'Neill RA, Maxwell AP, Paterson EN, et al. (2021) Retinal microvascular parameters are not
410 significantly associated with mild cognitive impairment in the Northern Ireland Cohort for the Longitudinal
411 Study of Ageing. *BMC Neurol* 21(1): 112. 10.1186/s12883-021-02137-4
- 412 [36] Drobnjak D, Munch IC, Glümer C, et al. (2016) Retinal Vessel Diameters and Their Relationship
413 with Cardiovascular Risk and All-Cause Mortality in the Inter99 Eye Study: A 15-Year Follow-Up. *J Ophthalmol*
414 2016: 6138659. 10.1155/2016/6138659
- 415 [37] Liew G, Gopinath B, White AJ, Burlutsky G, Yin Wong T, Mitchell P (2021) Retinal Vasculature
416 Fractal and Stroke Mortality. *Stroke* 52(4): 1276-1282. 10.1161/strokeaha.120.031886
- 417 [38] Olafsdottir OB, Saevarsdottir HS, Hardarson SH, et al. (2018) Retinal oxygen metabolism in
418 patients with mild cognitive impairment. *Alzheimers Dement (Amst)* 10: 340-345. 10.1016/j.dadm.2018.03.002
- 419

Table 1: Descriptive data of individuals and eyes with and without mild cognitive impairment (MCI) in persons with type 2 diabetes.

	MCI		p-value
	Yes	No	
Individuals, n	38	96	
Sex, male %(n)	61% (23)	74% (71)	0.13
Age, years median (IQR)	74.0 (70.0, 75.0)	71.5 (68.5, 76.0)	0.20
Current partner status %(n)			0.39
Single	29% (11)	22% (21)	
Married or living together	71% (27)	78% (75)	
History of ischemic heart disease %(n)	24% (9)	20% (19)	0.62
Diabetes duration (years), median (IQR)	19.0 (14.0, 24.0)	19.0 (13.0, 23.0)	0.50
Years of education, median (IQR)	9.0 (7.0, 11.0)	11.0 (10.0, 13.0)	<0.001
BMI (kg/m ²), median (IQR)	28.8 (26.0, 31.2)	29.5 (26.1, 33.5)	0.45
Smoking %(n)			0.49
Current	5% (2)	9% (9)	
Never	34% (13)	41% (39)	
Former	61% (23)	50% (48)	
MAP (mmHg), median (IQR)	101.2 (93.3, 107.3)	102.0 (94.0, 109.5)	0.67
Abdominal circumference (Cm), median (IQR)	104.0 (100.0, 112.0)	108.0 (98.0, 118.0)	0.49
GDS-15, median (IQR)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	0.46
MoCA, median (IQR)	23.0 (21.0, 24.0)	26.0 (25.0, 27.0)	<0.001
Medication use %(n):			
Antihypertensive treatment			
No therapy	13% (5)	14% (13)	0.95
Mono therapy	26% (10)	16% (15)	0.15
Two-drug therapy	24% (9)	34% (33)	0.23
Three or more drug therapy	37% (14)	36% (35)	0.97
Antidiabetic treatment			
Glucose lowering treatment excluding insulin	97% (37)	83% (80)	0.028
Insulin treatment	45% (17)	53% (51)	0.38
Statin treatment	84% (32)	80% (76)	0.57
Laboratory tests:			
HbA _{1c} (%), median (IQR)	7.1 (6.7, 8.4)	7.3 (6.7, 7.9)	0.96
HbA _{1c} (mmol/mol), median (IQR)	54.5 (50.0, 68.0)	56.0 (50.0, 62.5)	
Total cholesterol (mmol/L), median (IQR)	3.7 (3.2, 4.2)	3.6 (3.2, 4.3)	0.85
LDL cholesterol (mmol/L), median (IQR)	1.5 (1.2, 2.0)	1.5 (1.3, 2.0)	0.73
HDL cholesterol (mmol/L), median (IQR)	1.3 (1.2, 1.6)	1.2 (1.0, 1.6)	0.32
Triglycerides (mmol/L), median (IQR)	1.6 (1.1, 2.1)	1.5 (1.1, 2.0)	0.80
eGFR (ml/min/1.73 m ²), median (IQR)	75.0 (59.0, 87.0)	77.0 (57.5, 88.0)	0.99
Albumin excretion rate (mg/g), %(n)			0.28
<30	79% (30)	76% (73)	
30-300	21% (8)	18% (17)	
>300	0% (0)	6% (6)	
Eyes included, n	71	174	

Pseudophakia, %(n)	35.2% (25)	29.9% (52)	0.42
BCVA ETDRS letters, median (IQR)	84.0 (80.0, 85.0)	84.5 (82.0, 87.0)	0.035
Diabetic retinopathy, ICDR %(n)			0.29
Level 0	22.5% (16)	35.1% (61)	
Level 1	22.5% (16)	19.5% (34)	
Level 2	52.1% (37)	42.5% (74)	
Level 3	2.8% (2)	2.9% (5)	

Missing data: Abdominal circumference (n=1), Total cholesterol (n=1), LDL cholesterol (n=2), eGFR (n=1), albumin excretion rate (n=1). IQR: Interquartile range. ICDR: the International Clinical Diabetic Retinopathy. MAP: Mean arterial pressure. GDS-15: Geriatric depression scale. BMI: Body mass index. eGFR: estimated glomerular filtration. BCVA: Best corrected visual acuity. ETDRS: Early Treatment Diabetic Retinopathy Study.

Table 2 – Difference in retinal macular layers in individuals with type 2 diabetes with and without mild cognitive impairment (MCI).

	n	MCI yes	MCI no	P-value crude model	P-value multivariate adjusted model
Central retinal thickness					
Whole macular area	243	302.6 (297.7-307.5)	307.1 (303.7-310.5)	0.048	0.145
Central macular region, 1mm	243	279.4 (273.6-285.1)	285.0 (280.5-289.5)	0.049	0.130
Inner region, 3mm	243	326.3 (320.7-331.8)	332.1 (328.4-335.8)	0.024	0.092
Superior	243	327.4 (322.1-332.7)	335.4 (331.6-339.2)	0.007	0.018
Nasal	243	330.9 (325.2-336.6)	338.5 (334.7-342.3)	0.011	0.033
Inferior	242	325.7 (319.8-331.5)	328.9 (323.6-334.1)	0.139	0.466
Temporal	243	320.4 (314.7-326.1)	325.5 (321.8-329.3)	0.050	0.144
Outer region, 6mm	243	284.5 (279.5-289.5)	287.5 (284.1-291.0)	0.183	0.329
Superior	243	286.9 (281.5-292.2)	291.9 (288.2-295.7)	0.081	0.129
Nasal	243	297.5 (291.9-303.2)	302.3 (298.5-306.1)	0.128	0.174
Inferior	241	276.4 (271.0-281.9)	275.5 (271.2-279.8)	0.871	0.811
Temporal	242	276.1 (271.1-281.1)	280.3 (276.7-283.8)	0.078	0.183
Macula RNFL					
Whole macular area	243	25.8 (24.7-26.9)	27.1 (26.3-27.9)	0.141	0.055
Central macular region, 1mm	243	12.8 (12.2-13.4)	13.3 (12.9-13.8)	0.150	0.199
Inner region, 3mm	243	21.3 (20.4-22.2)	22.4 (21.7-23.2)	0.061	0.045
Superior	242	22.3 (21.2-23.3)	24.1 (23.2-25.0)	0.018	0.007
Nasal	243	20.5 (19.7-21.4)	21.7 (20.9-22.4)	0.054	0.049
Inferior	242	23.9 (22.6-25.2)	25.3 (24.4-26.2)	0.118	0.087
Temporal	243	18.4 (17.9-19.0)	18.6 (18.0-19.3)	0.599	0.590
Outer region, 6mm	243	33.6 (32.0-35.3)	35.2 (34.1-36.4)	0.345	0.121
Superior	242	34.9 (32.5-37.3)	36.4 (35.1-37.7)	0.564	0.282
Nasal	243	43.3 (40.9-45.6)	46.5 (44.7-48.3)	0.121	0.032
Inferior	241	36.0 (34.1-37.8)	37.4 (36.0-38.8)	0.533	0.216
Temporal	242	20.0 (19.5-20.6)	20.6 (19.9-21.2)	0.362	0.218
Macula GCL					

Whole macular area	243	35.4 (34.0-36.9)	37.1 (36.1-38.1)	0.036	0.055
Central macular region, 1mm	243	15.4 (14.3-16.4)	16.5 (15.5-17.6)	0.067	0.110
Inner region, 3mm	243	44.2 (42.2-46.2)	46.8 (45.5-48.1)	0.021	0.029
Superior	243	45.6 (43.6-47.6)	48.4 (47.0-49.8)	0.019	0.021
Nasal	243	44.6 (42.5-46.6)	47.7 (46.5-49.0)	0.013	0.010
Inferior	242	45.3 (43.5-47.1)	47.8 (46.5-49.2)	0.033	0.027
Temporal	243	41.0 (38.7-43.3)	43.5 (42.2-44.7)	0.056	0.066
Outer region, 6mm	243	31.6 (30.3-32.9)	32.5 (31.7-33.3)	0.181	0.258
Superior	243	31.6 (30.2-33.0)	32.1 (31.3-32.9)	0.408	0.555
Nasal	243	33.3 (31.8-34.7)	34.6 (33.6-35.5)	0.138	0.149
Inferior	240	29.8 (28.6-31.0)	30.1 (29.5-30.8)	0.683	0.670
Temporal	241	31.6 (30.1-33.2)	33.0 (32.1-33.9)	0.119	0.143

Main analysis adjusted for sex, age, mean arterial pressure and present diabetic retinopathy. n: number of eyes included in the analysis. RNFL: Retinal nerve fiber layer. GCL: Ganglion cell layer. P-values still statistical significant after Bonferroni correction are annotated with a * (no statistical significant results after Bonferroni correction).

Table 3: Difference in retinal vascular markers in individuals with type 2 diabetes with and without mild cognitive impairment (MCI).

	n	MCI yes	MCI no	P-value crude model	P-value adjusted model
Vessel caliber (pixels)					
Arterioles	245	26.40 (25.77-27.02)	26.60 (26.28-26.92)	0.652	0.567
Venules	245	36.86 (35.7-38.00)	36.87 (36.31-37.43)	0.891	0.984
Vessel Tortuosity					
Arterial	245	-7.39 (-8.05-(-6.73))	-7.63 (-8.04-(-7.22))	0.821	0.547
Venular	245	-7.83 (-8.46-(-7.21))	-8.18 (-8.41-(-7.95))	0.383	0.313
Vessel Density (pixels)					
Arterioles	245	3413.61 (3194.18-3633.04)	3538.89 (3391.43-3686.35)	0.464	0.365
Venules	245	4608.35 (4288.18-4928.52)	4452.25 (4269.42-4635.08)	0.529	0.405
Fractal Dimension					
Arterioles	212	1.15 (1.13-1.17)	1.15 (1.14-1.16)	0.692	0.612
Venules	241	1.15 (1.13-1.17)	1.15 (1.14-1.16)	0.919	0.774
Total (Arterioles+venules)	245	1.31 (1.30-1.32)	1.32 (1.31-1.33)	0.402	0.327
DR yes	168	1.32 (1.30-1.33)	1.32 (1.31-1.33)	0.283	0.394
DR no	77	1.30 (1.26-1.33)	1.31 (1.29-1.32)	0.550	0.602

Main analysis adjusted for sex, age, mean arterial pressure and present diabetic retinopathy. In case of interaction, individuals were stratified in groups with and without diabetic retinopathy. n: number of eyes included in the analysis. DR: Diabetic retinopathy. P-values still statistical significant after Bonferroni correction are annotated with a * (no statistical significant results after Bonferroni correction).

Table 4: Difference in retinal structural markers in individuals with type 2 diabetes with and without mild cognitive impairment (MCI).

Superficial capillary plexus	n	MCI yes	MCI no	P-value crude model	P-value adjusted model
FAZ area (mm ²)	245	0.34 (0.28-0.41)	0.40 (0.32-0.49)	0.262	0.273
Vascular Density					
Circle	245	0.66 (0.63-0.69)	0.66 (0.64-0.68)	0.966	0.783
Core	245	0.34 (0.30-0.37)	0.31 (0.29-0.33)	0.295	0.261
Superior sector	245	0.71 (0.68-0.75)	0.71 (0.69-0.73)	0.982	0.849
Right sector	245	0.70 (0.66-0.75)	0.70 (0.67-0.72)	0.864	0.816
Inferior sector	245	0.65 (0.61-0.68)	0.65 (0.62-0.67)	0.867	0.987
Left sector	245	0.69 (0.65-0.72)	0.68 (0.66-0.71)	0.884	0.921
Non-perfusion area (mm²)					
Circle	245	4.34 (3.95-4.73)	4.40 (4.19-4.61)	0.988	0.777
Core	245	0.52 (0.49-0.55)	0.54 (0.52-0.56)	0.301	0.265
Superior sector	245	0.86 (0.74-0.97)	0.87 (0.80-0.94)	0.951	0.867
Right sector	245	0.90 (0.76-1.04)	0.92 (0.84-0.99)	0.909	0.811
Inferior sector	245	1.00 (0.89-1.11)	1.03 (0.95-1.11)	0.980	0.732
Left sector	245	1.04 (0.93-1.15)	1.03 (0.95-1.11)	0.708	0.914
Fractal dimension	245	1.68 (1.67-1.68)	1.67 (1.67-1.68)	0.818	0.567
Deep capillary plexus					
FAZ area (mm ²)	245	0.60 (0.50-0.70)	0.61 (0.55-0.66)	0.886	0.895
Vascular Density					
Circle	245	0.49 (0.48-0.51)	0.49 (0.48-0.50)	0.780	0.703
Core	245	0.21 (0.17-0.25)	0.19 (0.17-0.21)	0.265	0.360
Superior sector	245	0.54 (0.52-0.57)	0.54 (0.53-0.56)	0.705	0.928
Right sector	245	0.50 (0.47-0.53)	0.50 (0.49-0.51)	0.969	0.982
Inferior sector	245	0.48 (0.46-0.51)	0.48 (0.46-0.49)	0.746	0.750
Left sector	245	0.51 (0.49-0.53)	0.50 (0.49-0.51)	0.581	0.568
Non-perfusion area (mm²)					

Circle	245	7.62 (7.33-7.91)	7.80 (7.66-7.95)	0.334	0.291
Core	245	0.62 (0.59-0.65)	0.64 (0.62-0.65)	0.265	0.360
Superior sector	245	1.69 (1.60-1.77)	1.69 (1.64-1.73)	0.853	0.979
Right sector	245	1.67 (1.56-1.79)	1.77 (1.71-1.83)	0.156	0.139
Inferior sector	245	1.77 (1.67-1.87)	1.82 (1.76-1.89)	0.491	0.365
Left sector	245	1.84 (1.75-1.93)	1.85 (1.80-1.90)	0.857	0.844
Fractal dimension	245	1.71 (1.71-1.72)	1.71 (1.71-1.71)	0.846	0.571

Main analysis adjusted for sex, age, mean arterial pressure and present diabetic retinopathy. n: number of eyes included in the analysis. DR: Diabetic retinopathy. P-values still statistical significant after Bonferroni correction are annotated with a * (no statistical significant results after Bonferroni correction).

Table 5 – Difference in retinal vascular oximetry in individuals with type 2 diabetic with and without mild cognitive impairment (MCI).

	n	MCI yes	MCI no	P-value crude model	P-value adjusted model
Mean retinal arterial saturation (%):	243	89.92 (88.34-91.51)	91.43 (90.30-92.56)	0.470	0.144
DR yes	166	90.96 (89.57-92.34)	92.46 (90.94-93.98)	0.397	0.165
DR no	77	88.10 (84.00-92.19)	89.30 (88.00-90.53)	0.676	0.594
Mean retinal venular saturation (%):	243	53.40 (50.31-56.48)	56.17 (54.47-57.86)	0.429	0.132
DR yes	166	55.60 (52.71-58.48)	57.43 (55.23-59.64)	0.567	0.326
DR no	77	50.66 (43.25-58.07)	52.87 (50.69-55.06)	0.837	0.579
Arterial saturation quadrant analysis (%):					
Upper nasal	242	93.20 (91.20-95.19)	94.71 (93.55-95.86)	0.547	0.207
DR yes	165	94.86 (92.92-96.80)	95.63 (94.16-97.09)	0.832	0.541
DR no	77	89.74 (85.50-93.98)	92.80 (91.14-94.45)	0.215	0.192
Lower nasal	237	91.68 (89.53-93.82)	94.40 (91.53-97.28)	0.252	0.179
DR yes		No interaction	No interaction		
DR no		No interaction	No interaction		
Upper temporal	243	89.75 (86.84-90.90)	89.75 (88.47-91.02)	0.963	0.488
DR yes	166	90.03 (88.10-91.96)	90.72 (89.07-92.37)	0.933	0.601
DR no	77	87.71 (82.67-92.75)	87.67 (85.81-89.52)	0.934	0.988
Lower temporal	239	85.93 (84.11-87.75)	87.08 (85.67-88.49)	0.709	0.327
DR yes	162	86.70 (84.44-88.96)	88.00 (86.33-89.67)	0.531	0.363
DR no	77	84.30 (80.03-88.58)	84.92 (82.65-87.19)	0.863	0.802
Venular saturation quadrant analysis (%):					
Upper nasal	241	56.40 (52.94-59.87)	60.93 (59.06-62.80)	0.131	0.028
DR yes	164	58.83 (55.37-62.30)	62.38 (59.99-64.78)	0.165	0.100
DR no	77	52.57 (45.18-60.00)	57.61 (55.34-59.96)	0.465	0.203
Lower nasal	241	56.53 (52.66-60.41)	56.63 (54.56-58.70)	0.776	0.967
DR yes		No interaction	No interaction		
DR no		No interaction	No interaction		
Upper temporal	242	52.76 (49.56-55.96)	56.19 (54.16-58.230)	0.409	0.083
DR yes	165	55.01 (52.05-57.96)	58.14 (55.60-60.67)	0.358	0.117
DR no	77	48.95 (41.37-56.54)	51.87 (48.89-54.85)	0.656	0.491
Lower temporal	238	47.49 (43.34-51.65)	51.05 (48.60-53.49)	0.430	0.153
DR yes	163	50.15 (45.75-54.54)	52.72 (49.78-55.67)	0.412	0.341
DR no	75	45.07 (36.05-54.10)	46.57 (42.72-50.42)	0.979	0.769

Main analysis adjusted for sex, age, mean arterial pressure and present diabetic retinopathy. In case of interaction, individuals were stratified in groups with and without diabetic retinopathy. N: number of eyes included in the analysis. DR: Diabetic retinopathy. P-values still statistical significant after Bonferroni correction are annotated with a * (no statistical significant results after Bonferroni correction).

Figure legends:

Figure 1: Flowchart of individuals included in the study.

Figure 2: Boxplot of domain scores in persons with type 2 diabetes with and without mild cognitive impairment.